197A

TAUNS Laboratories,Inc.

タウンズ

Industry
Pharmaceutical
Market
Standard
Accounting standards
Japanese GAAP
Consolidation basis
Non-consolidated

Key metrics

Revenue(thousand JPY)

Jun 2024
18,434,863
Jun 2025
18,627,990

Operating profit(thousand JPY)

Jun 2024
8,030,094
Jun 2025
8,265,025

Operating profit margin(%)

Jun 2024
43.56
Jun 2025
44.37

Profit before tax(thousand JPY)

Jun 2024
7,834,691
Jun 2025
8,201,875

Profit(thousand JPY)

Jun 2024
5,774,086
Jun 2025
6,315,407

Total assets(thousand JPY)

Jun 2024
29,261,325
Jun 2025
36,515,294

Cash and cash equivalents(thousand JPY)

Jun 2024
9,424,891
Jun 2025
9,266,630

Cash flows from operating activities(thousand JPY)

Jun 2024
9,935,074
Jun 2025
6,818,472

Cash flows from investing activities(thousand JPY)

Jun 2024
-4,110,382
Jun 2025
-9,258,084

Cash flows from financing activities(thousand JPY)

Jun 2024
2,355,823
Jun 2025
2,281,350

Return on equity(%)

Jun 2024
52.2
Jun 2025
40.7

Equity ratio(%)

Jun 2024
46.7
Jun 2025
47.7

Earnings per share(JPY per share)

Jun 2024
57.74
Jun 2025
62.07

Net assets per share(JPY per share)

Jun 2024
136.53
Jun 2025
168.99

Dividend per share(JPY per share)

Jun 2024
27.75
Jun 2025
28

Payout ratio(%)

Jun 2024
48.06
Jun 2025
45.11

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.